Shenzhen Sinobio Biopharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Shenzhen Sinobio Biopharmaceutical - overview
Established
2024
Location
Shenzhen, Guangdong, China
Primary Industry
Biotechnology
About
Founded in 2024 and based in Shenzhen, China, Shenzhen Sinobio Biopharmaceutical operates as a biotechnology service provider focusing on the research and development of recombinant botulinum toxin. In May 2025, the company closed an angel funding. Shenzhen Sinobio Biopharmaceutical has an exclusive green preparation process for synthetic biology-botulinum toxin, an AI botulinum protein design and directed evolution platform, a botulinum protein function high-throughput screening platform, and a number of independent recombinant botulinum toxin core technologies.
Current Investors
Green Pine Capital Partners, Leaguer Group, Shenzhen Qianhai Star River Capital Management Co., Ltd.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.